Dendreon Pharmaceuticals LLC
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$16.3M
Doctors Paid
9,514
Transactions
61,024
2024 Total
$1.8M
Payment Breakdown by Category
Research$11.5M (70.7%)
Food & Beverage$1.6M (10.1%)
Consulting$959,142 (5.9%)
Travel$239,345 (1.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $11.5M | 1,762 | 70.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.9M | 896 | 11.8% |
| Food and Beverage | $1.6M | 57,082 | 10.1% |
| Consulting Fee | $959,142 | 406 | 5.9% |
| Travel and Lodging | $239,345 | 742 | 1.5% |
| Education | $2,108 | 136 | 0.0% |
Payments by Type
Research
$11.5M
1,762 transactions
General
$4.8M
59,262 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| OPEN- LABEL TRIAL OF SIPULEUCEL-T ADMINISTERED TO ACTIVE SURVEILLANCE PATIENTS FOR NEWLY DIAGNOSED PROSTATE CANCER PROVENT | $3.2M | 0 | 295 |
| A RANDOMIZED PHASE 3, OPEN-LABEL TRIAL OF SIPULEUCEL-T ADMINISTERED TO PATIENTS ON ACTIVE SURVEILLANCE FOR NEWLY DIAGNOSED PROSTATE CANCER | $2.9M | 0 | 751 |
| OPEN- LABEL TRIAL OF SIPULEUCEL-T ADMINISTERED TO ACTIVE SURVEILLANCE PATIENTS FOR NEWLY DIAGNOSED PROSTATE CANCER (PROVENT) | $2.4M | 0 | 392 |
| A RANDOMIZED PHASE 2 STUDY OF SIPULEUCEL-T WITH OR WITHOUT RADIUM-223 IN MEN WITH ASYMPTOMATIC OR MINIMALLY SYMPTOMATIC BONE-METASTATIC CASTRATE-RESISTANT PROSTATE CANCER | $695,523 | 0 | 14 |
| ProvONE Study | $684,938 | 0 | 88 |
| A RANDOMIZED PHASE 2 TRIAL OF IMMEDIATE VS. DELAYED ANTI-CTLA4 BLOCKADE FOLLOWING SIPULEUCEL-T TREATMENT FOR PROSTATE CANCER IMMUNOTHERAPY | $213,299 | 0 | 5 |
| A STUDY TO EVALUATE CHARACTERISTICS PREDICTIVE OF A POSITIVE IMAGING STUDY FOR DISTANT METASTASES IN PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER PREDICT | $177,661 | 1 | 72 |
| BIOLOGIC TISSUE EFFECT OF SIPULEUCEL-T ON METASTATIC CASTRATION-RESISTANT PROSTATE CANCER | $147,752 | 0 | 9 |
| Biologic Tissue Effect OF Sipuleucel-T on Metastatic Castration-resistant Prostate Cancer | $147,686 | 0 | 2 |
| EVALUATION OF LYMPH NODE METASTAASES IN MEN UNDERGOING TREATMENT WITH SIPULEUCEL-T FOR METASTATIC CASTRATED-RESISTANT PROSTATE CANCER | $138,222 | 0 | 1 |
| IMMUNE EVALUATION STUDY OF SIPULEUCEL-T IN AFRICAN AMERICAN MEN WITH CASTRATE RESISTANT PROSTATE CANCER | $127,500 | 0 | 1 |
| CLINICAL STUDY OF ATEZOLIZUMAB ANTI-PD-L1 AND SIPULEUCEL-T IN PATIENTS WHO HAVE ASYMPTOMATIC OR MINIMALLY SYMPTOMATIC METASTATIC CASTRATE RESISTANT PROSTATE CANCER | $120,135 | 0 | 9 |
| A Phase II CTLA4 Blockade Combined with Sipuleucel-T (Provenge) for Prostate Cancer Immunotherapy | $91,720 | 0 | 2 |
| RETROSPECTIVE REVIEW EVALUATING THE PSA CHANGES IN PATIENT WITH METASTATIC CASTRATE RESISTANT PROSTATE CANCER AFTER SIPULEUCEL-T TREATMENT | $79,514 | 0 | 1 |
| CYT107 AFTER VACCINE TREATMENT PROVENGE IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER | $66,796 | 0 | 1 |
| ROSSER-2015-4CLINICAL STUDY OF ATEZOLIZUMAB (ANTI-PD-L1) AND SIPULEUCEL-T IN PATIENTS WHO HAVE ASYMPTOMATIC OR MINIMALLY SYMPTOMATIC METASTATIC CASTRATE RESISTANT PROSTATE CANCER | $58,159 | 0 | 2 |
| IMPACT OF HIGH-DOSE, SINGLE FRACTION RADIATION ON IMMUNOGENICITY OF SIPULEUCEL-T IN METASTATIC CASTRATION RECURRENT PROSTATE CANCER PATIENTS | $42,609 | 0 | 1 |
| A PHASE II CTLA4 BLOCKADE COMBINED WITH SIPULEUCEL-T PROVENGE FOR PROSTATE CANCER IMMUNOTHERAPY | $41,477 | 0 | 1 |
| A RANDOMIZED, OPEN-LABEL, PHASE 2 TRIAL OF SIPULEUCEL-T WITH CONCURRENT VERSUS SEQUENTIAL ADMINISTRATION OF ABIRATERONE ACETATE PLUS PREDNISONE IN MEN WITH METASTATIC CASTRATE RESISTANT PROSTATE CANCER | $31,613 | 0 | 49 |
| A PHASE II RANDOMIZED STUDY OF SIPULEUCEL-T WITH OR WITHOUT CONTINUING NEW HORMONAL AGENTS (NHA) IN METASTATIC PROSTATE CANCER WITH PSA PROGRESSION WHILE ON NHA AND LHRH ANALOG | $31,245 | 0 | 1 |
| A REGISTRY OF SIPULEUCEL-T THERAPY IN MEN WITH ADVANCED PROSTATE CANCER | $28,120 | 0 | 21 |
| PILOT TRIAL OF SIPULEUCEL-T, WITH OR WITHOUT PTVG-HP DNA BOOSTER VACCINE, IN PATIENTS WITH CASTRATE-RESISTANT, METASTATIC PROSTATE CANCER | $26,266 | 0 | 1 |
| CLINICAL STUDY OF ATEZOLIZUMAB (ANTI-PD-L1) AND SIPULEUCEL-T IN PATIENTS WHO HAVE ASYMPTOMATIC OR MINIMALLY SYMPTOMATIC METASTATIC CASTRATE RESISTANT PROSTATE CANCER | $19,645 | 0 | 4 |
| A STUDY OF SIPULEUCEL-T WITH ADMINISTRATION OF ENZALUTAMIDE IN MEN WITH METASTATIC CASTRATE-RESISTANT PROSTATE CANCER | $14,454 | 0 | 4 |
| A RANDOMIZED, OPEN LABEL, PHASE 2 STUDY OF SIPULEUCEL-T WITH CONCURRENT VERSUS SEQUENTIAL ADMINISTRATION OF ENZALUTAMIDE IN MEN WITH METASTATIC CASTRATE-RESISTANT PROSTATE CANCER | $11,680 | 0 | 25 |
| DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2 Urothelial Carcinoma | $6,845 | 0 | 1 |
| IMMUNE MONITORING PROTOCOL IN MEN WITH PROSTATE CANCER ENROLLED IN A CLINICAL TRIAL OF SIPULEUCEL-T | $1,539 | 0 | 8 |
| A SYSTEMS BIOLOGY APPROACH TO IMMUNE MONITORING IN PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER RECEIVING SIPULEUCEL-T | $1,200 | 0 | 1 |
Payments by Medical Specialty
Top Paid Doctors — Page 2
| Doctor | Specialty | Location | Total | 2024 |
|---|---|---|---|---|
| Dr. Sumit Subudhi, Md, Phd, MD, PHD | Medical Oncology | Houston, TX | $42,187 | $0 |
| Dr. Tim Richardson, Md, MD | Urology | Wichita, KS | $37,408 | $0 |
| Andrew Armstrong, Md, MD | Medical Oncology | Durham, NC | $34,972 | $0 |
| Dr. Mark Jalkut, Md, MD | Urology | Raleigh, NC | $33,708 | $0 |
| Gary Kirsh, Md, MD | Urology | Blue Ash, OH | $29,749 | $0 |
| Deepak Kapoor, Md, MD | Urology | Bethpage, NY | $29,703 | $0 |
| Dr. Matthew Collins, Md, MD | Urology | Greenville, NC | $27,868 | $0 |
| Dr. Jingsong Zhang, M.d, M.D | Medical Oncology | Tampa, FL | $27,860 | $0 |
| Dr. Jacek Pinski, M.d, M.D | Medical Oncology | Los Angeles, CA | $23,636 | $0 |
| Dr. Kelvin Moses, M.d., Ph.d, M.D., PH.D | Urology | Nashville, TN | $23,352 | $0 |
| Dr. Damian Sorce, Md, MD | Urology | Parker, CO | $22,713 | $0 |
| Dr. James Tycast, M.d, M.D | Urology | Portland, OR | $22,344 | $0 |
| Carlton Barnswell, Md, MD | Urology | Elmont, NY | $21,806 | $0 |
| Mahdi Taha, D.o, D.O | Medical Oncology | Deerfield Beach, FL | $21,793 | $0 |
| Dr. Scott Sellinger, Md, MD | Urology | Tallahassee, FL | $21,471 | $0 |
| Dr. Daniel Saltzstein, Md, MD | Surgery | San Antonio, TX | $19,908 | $0 |
| Paul Schellhammer, M.d, M.D | Urology | Va Beach, VA | $16,921 | $0 |
| Joseph Renzulli, Md, MD | Urology | Providence, RI | $15,688 | $0 |
| Todd Yezefski, M.d, M.D | Hematology & Oncology | Seattle, WA | $14,221 | $0 |
| Daniel Voglewede, M.d, M.D | Urology | El Paso, TX | $14,165 | $0 |
| Rana Mckay, Md, MD | Hematology & Oncology | San Diego, CA | $12,554 | $0 |
| Dr. Kenneth Ney, M.d, M.D | Urology | Carmel, IN | $11,665 | $0 |
| Dr. Alec Koo, M.d, M.D | Urology | Torrance, CA | $11,052 | $0 |
| Dr. Thomas Hutson, Do,Pharmd, DO,PHARMD | Medical Oncology | Dallas, TX | $10,640 | $0 |
| Dr. Matthew Cooperberg, Md, MD | Urology | San Francisco, CA | $10,383 | $0 |
About Dendreon Pharmaceuticals LLC
Dendreon Pharmaceuticals LLC has made $16.3M in payments to 9,514 healthcare providers, recorded across 61,024 transactions in the CMS Open Payments database. In 2024, the company paid $1.8M. The top product by payment volume is PROVENGE ($16.1M).
Payments were distributed across 144 medical specialties. The top specialty by payment amount is Urology ($3.3M to 3,858 doctors).
Payment categories include: Food & Beverage ($1.6M), Consulting ($959,142), Research ($11.5M), Travel & Lodging ($239,345).
Dendreon Pharmaceuticals LLC is associated with 1 products in the CMS Open Payments database.